ReviewBritish journal of clinical pharmacology2014
Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms.
Review in British journal of clinical pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 54 citations in OpenAlex.
- Association of DNA methylation in BDNF with escitalopram treatment response in depressed Chinese Han patients.European journal of clinical pharmacology · 2018Trial
- Disease-specific therapeutic plasma concentration ranges for quetiapine in schizophrenia, manic episode, depressive episode, and depressive comorbid insomnia.Discover mental health · 2026Article
- Pharmacogenomics of Major Depressive Disorder in Indigenous Amazonian Populations.Clinical pharmacology and therapeutics · 2026Article
- Neuromodulators Generate Multiple Context-Relevant Behaviors in Recurrent Neural Networks.Neural computation · 2026Article
- Obesity genetic association prospective cohort utilizing single center real-world evidence data.Medicine · 2025Article
- Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic Treatments.Pharmacopsychiatry · 2025Article
- Uncovering Functional Contributions of PMAT (Cells · 2022Article
- Preclinical neuroimaging of gene-environment interactions in psychiatric disease.The British journal of radiology · 2019Review
- Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression.Frontiers in pharmacology · 2019Article
- Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools.The pharmacogenomics journal · 2018Article
- Neuropsychiatric disease-associated genetic variants of the dopamine transporter display heterogeneous molecular phenotypes.The Journal of biological chemistry · 2018Article
- Precision medicine: does ethnicity information complement genotype-based prescribing decisions?Therapeutic advances in drug safety · 2018Review
- Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns.European archives of psychiatry and clinical neuroscience · 2017Article
- Importance of Drug Pharmacokinetics at the Site of Action.Clinical and translational science · 2017Review
- The impact of common dopamine D2 receptor gene polymorphisms on D2/3 receptor availability: C957T as a key determinant in putamen and ventral striatum.Translational psychiatry · 2017Article
- Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs.Dialogues in clinical neuroscience · 2016Review
- Pharmacogenomics: A focus on antidepressants and atypical antipsychotics.The mental health clinician · 2016Article
- Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS).Molecular neurobiology · 2014Article
- GABA Receptors Genes Polymorphisms and Alcohol Dependence: No Evidence of an Association in an Italian Male Population.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2014Article
- Opportunities and limitations: the value of pharmacogenetics in clinical practice.British journal of clinical pharmacology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of severe mental illness, and of psychiatric disorders in general, is limited in its efficacy and tolerability. There appear to be substantial interindividual differences in response to psychiatric drug treatments that are generally far greater than the differences between individual drugs; likewise, the occurrence of adverse effects also varies profoundly between individuals. These differences are thought to reflect, at least in part, genetic variability. The action of psychiatric drugs primarily involves effects on synaptic neurotransmission; the genes for neurotransmitter receptors and transporters have provided strong candidates in pharmacogenetic research in psychiatry. This paper reviews some aspects of the pharmacogenetics of neurotransmitter receptors and transporters in the treatment of psychiatric disorders. A focus on serotonin, catecholamines and amino acid transmitter systems reflects the direction of research efforts, while relevant results from some genome-wide association studies are also presented. There are many inconsistencies, particularly between candidate gene and genome-wide association studies. However, some consistency is seen in candidate gene studies supporting established pharmacological mechanisms of antipsychotic and antidepressant response with associations of functional genetic polymorphisms in, respectively, the dopamine D2 receptor and serotonin transporter and receptors. More recently identified effects of genes related to amino acid neurotransmission on the outcome of treatment of schizophrenia, bipolar illness or depression reflect the growing understanding of the roles of glutamate and γ-aminobutyric acid dysfunction in severe mental illness. A complete understanding of psychiatric pharmacogenomics will also need to take into account epigenetic factors, such as DNA methylation, that influence individual responses to drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.